6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-{2-[3-ethyl-4-(1,3-thiazol-2-yloxy)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one | 877131-58-3

• 分子结构分类: 有机化合物
• 英文名称: 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-{2-[3-ethyl-4-(1,3-thiazol-2-yloxy)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one
• 英文别名: 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-[2-[3-ethyl-4-(1,3-thiazol-2-yloxy)phenyl]ethyl]-4-hydroxy-3H-pyran-6-one
• CAS: 877131-58-3
• 化学式: C₃₁H₃₅N₅O₄S
• 分子量: 573.716
• InChiKey: ZGFZLECJDLPLSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  41
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  140
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME<br/>[FR] INHIBITEURS DE POLYMERASE D'ARN DEPENDANT D'ARN DU VIRUS DE L'HEPATITE C ET COMPOSITIONS ET TRAITEMENT UTILISANT CES INHIBITEURS
  申请人：PFIZER

  公开号：WO2006018725A1

  公开（公告）日：2006-02-23

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了公式（4）的化合物，以及它们的药学上可接受的盐和溶剂化合物，这些化合物可用作肝炎病毒（HCV）聚合酶酶的抑制剂，并且也可用于治疗HCV感染的HCV感染的哺乳动物。本发明还提供了包含公式（4）的化合物、其药学上可接受的盐和溶剂的药物组合物。此外，本发明提供了制备公式（4）化合物的中间体化合物和方法。
• Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
  申请人：Gonzalez Javier

  公开号：US20060122399A1

  公开（公告）日：2006-06-08

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了式（4）的化合物及其药学上可接受的盐和溶剂，它们可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且对于治疗HCV感染的HCV感染的哺乳动物也有用。本发明还提供了包含式（4）的化合物、其药学上可接受的盐和溶剂的药物组合物。此外，本发明还提供了中间体化合物和用于制备式（4）化合物的有用方法。
• INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：Gonzalez Javier

  公开号：US20070015764A1

  公开（公告）日：2007-01-18

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了公式(4)的化合物及其药学上可接受的盐和溶剂，这些化合物可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且还可用于治疗HCV感染的HCV感染哺乳动物。本发明还提供了包含公式(4)的化合物、其药学上可接受的盐和溶剂的制药组合物。此外，本发明还提供了中间体化合物和制备公式(4)的方法。
• Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same
  申请人：Gonzalez Javier

  公开号：US20090281122A1

  公开（公告）日：2009-11-12

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了式（4）的化合物及其药学上可接受的盐和溶剂化物，它们可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且也可用于治疗HCV感染的HCV感染的哺乳动物。本发明还提供了包含式（4）的化合物、它们的药学上可接受的盐和溶剂化物的制药组合物。此外，本发明还提供了用于制备式（4）的化合物的中间体和方法。
• US7151105B2
  申请人：——

  公开号：US7151105B2

  公开（公告）日：2006-12-19